Search
Nafcillin
go.drugbank.com/drugs/DB00607ApprovedInvestigationalIt may be used as a first-line therapy in Methicillin-Sensitive *Staphylococcus aureus* infections [A20360].
Iroxanadine
go.drugbank.com/drugs/DB05444ExperimentalBRX-235 (iroxanadine) is a a novel small molecule synthesized by Biorex, Hungary that acts as a cardioprotective agent.
NRP409
go.drugbank.com/drugs/DB05235ExperimentalNRP409 is a triiodothyronine (T3) hormone, being investigated by New River Pharmaceuticals as a treatment for patients with primary hypothyroidism.
NGD-4715
go.drugbank.com/drugs/DB06027ExperimentalNGD-4715 functions as a melanin-concentrating hormone receptor 1 antagonist.
4-Hydroxytestosterone
go.drugbank.com/drugs/DB01485IllicitInvestigationalFormestane (Lentaron) acts as a prohormone of 4-Hydroxytestosterone, as 4-Hydroxytestosterone is one of the many byproducts of formestane metabolism.
Tyrosine
go.drugbank.com/drugs/DB00135ApprovedInvestigationalNutraceuticalTyrosine is a non-essential amino acid. In animals it is synthesized from phenylalanine. It is also the precursor of epinephrine, thyroid hormones, and melanin.
Etacrynic acid
go.drugbank.com/drugs/DB00903ApprovedInvestigationalThis compound has been classified as a loop or high ceiling diuretic.
Almitrine
go.drugbank.com/drugs/DB01430ApprovedAlmitrine is a respiratory stimulant that enhances respiration by acting as an agonist of peripheral chemoreceptors located on the carotid bodies.
Levallorphan
go.drugbank.com/drugs/DB00504ApprovedIt should be used cautiously; levallorphan reverses severe opioid-induced respiratory depression but may exacerbate respiratory depression such as that induced by alcohol or other non-opioid central depressants
Lenvatinib
go.drugbank.com/drugs/DB09078ApprovedInvestigationalThese receptor tyrosine kinases (RTKs) located in the cell membrane play a central role in the activation of signal transduction pathways involved in the normal regulation of cellular processes, such as … However, for patients with RAI-refractory thyroid cancer, treatment options are limited and the prognosis is poor, leading to a push for the development of more targeted therapies such as lenvatinib.